Does montelukast reduce the treatment cost in children with moderately severe atopic dermatitis

Current Pediatric Research

Volumn 12, Issue 1-2, 2008, Pages 1-4

  Ehlayel, Mohammad S ^a   Bener, Abdulbari ^b,c  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b HAMAD GENERAL HOSPITAL   (Qatar)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atopic dermatitis; Children; Moderate; Montelukast; Severe

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; MONTELUKAST; PLACEBO; STEROID;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY;

EID: 51049101472     PISSN: 09719032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol 2005; 53 Suppl 1: 86-93.
2. Kemp AS. Atopic dermatitis: its social and financial costs. J Paediatr Child Health 1999; 35: 229-231.
3. Chamlin SL, Mattson CL, Frieden IJ, Williams ML, Mancici AJ, Cella D, et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Paediatr Adolesc Med 2005; 159: 745-750.
4. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. The cost of atopic dermatitis. Br J Dermatol 1996; 135: 20-23.
5. Coyle D, Barbeau M. Cost-effectiveness of Elidel in the management of patients with atopic dermatitis in Canada. J Cut Med Surg 2004; 8: 405-410.
6. Broshtilova V, Antonov D, Bardarov E, Tsankov N. Severe erythrodermic atopic dermatitis treated with montelukast. Skin Med 2003; 2: 134-136.
7. Angelova-Fischer I, Tsankov N. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast. Acta Dermatoven APA 2005; 14: 115-119.
8. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venereol (Stockh) 1980; Suppl 92: 44-47.
9. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001; 12: 154-158.
10. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001; 44: 89-93.
11. Busse WW, Casale TB, Dykewicz MS, Meltzer EO, Bird SR, Hustad CM, et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 2006; 96: 60-68.
12. Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737-742.
13. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Respir Med 2001; 95: 83-89.
14. Dal Negro R, Piskorz P, Vives R, M Guilera, Sazonov Kocevar V, Badia X. Healthcare utilization and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and comorbid allergic rhinitis: PRAACTICAL Study. Pharmacoeconomics 2007; 25: 665-676.
15. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002; 20: 909-918.
16. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002 109: 433-439.
17. O'Connor R, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22: 815-825.
18. Keskin O, Alyamac E, Tuncer A, Dogan C, Adalioglu G, Sekerel BE. Do the leukotriene receptor antagonists work in children with grass pollen-induced allergic rhinitis? Pediatr Allergy and Immunol 2006; 17: 259-268.
19. Martin BG, Andrews CP, van Bavel JH, Hampe FCI, Klein KC, Prillaman BA, et al. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol 2006; 96: 851-857.
20. Chen ST, Lu KH, Sun HL, Chang WT, Lue KH, Chou MC. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 2006; 17:591-598.
21. Hung CH, Hua YM, Hsu WT, Lai YS, Yang KD, Jong YJ, et al. Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis. Pediatr Int 2007; 49: 322-327.
22. Ciebiada M, Górska-Ciebiada M, DuBuske LM, Górski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 664-671.
23. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 360-367.